Search PubMedSearch

PubMed · 8074554

[Vancomycin].

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

[Vancomycin].. https://pubmed.ncbi.nlm.nih.gov/8074554/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Prophylactic removal of impacted third molars: an assessment of published reviews.

OBJECTIVE: To evaluate published reviews of the appropriateness of prophylactic removal of impacted third molars. DESIGN: Systematic review and critical appraisal of relevant reviews. METHODS: Computerised databases (Medline and Embase), the Index to Dental Literature, and the references of articles were searched to identify relevant reviews. MAIN OUTCOME MEASURES: Pathologies associated with impacted third molars and outcomes following surgical removal of third molars. RESULTS: Twelve published reviews were assessed. Major methodological problems in these include that authors did not describe review methods such as literature search strategy and criteria for inclusion of primary studies. Reviews with similar aims included different sets of primary studies as evidence. Details of primary studies quoted were seldom sufficient for readers to judge the reliability of the evidence. With the exception of two reviews with poorer quality, the reviews concluded that there is a lack of evidence to support the prophylactic removal of impacted third molars. Two decision analyses also concluded that, on average, patients' long-term wellbeing is maximised if extraction is confined to those impacted third molars with pathology. CONCLUSIONS: In the absence of good evidence to support prophylactic removal, there appears to be little justification for the removal of pathology-free impacted third molars.

Contraindications

Results of heart transplantation in patients with preexisting malignancies.

Twenty patients with end-stage heart failure and preexisting malignancies underwent heart transplantation at a single center, with a neoplasm-free interval before the procedure of 0 to 240 months. Twelve patients were long-term survivors (2 to 72 months); there were 2 early and 6 late deaths, thus justifying heart transplantation in patients with preexisting malignancies in individual cases.

Contraindications